Higher vitamin B6 status is associated with improved survival among patients with stage I-III colorectal cancer. was written by Holowatyj, Andreana N;Ose, Jennifer;Gigic, Biljana;Lin, Tengda;Ulvik, Arve;Geijsen, Anne J M R;Brezina, Stefanie;Kiblawi, Rama;van Roekel, Eline H;Baierl, Andreas;Böhm, Jürgen;Bours, Martijn J L;Brenner, Hermann;Breukink, Stéphanie O;Chang-Claude, Jenny;de Wilt, Johannes H W;Grady, William M;Grünberger, Thomas;Gumpenberger, Tanja;Herpel, Esther;Hoffmeister, Michael;Keulen, Eric T P;Kok, Dieuwertje E;Koole, Janna L;Kosma, Katharina;Kouwenhoven, Ewout A;Kvalheim, Gry;Li, Christopher I;Schirmacher, Peter;Schrotz-King, Petra;Singer, Marie C;van Duijnhoven, Fränzel J B;van Halteren, Henk K;Vickers, Kathy;Vogelaar, F Jeroen;Warby, Christy A;Wesselink, Evertine;Ueland, Per M;Ulrich, Alexis B;Schneider, Martin;Habermann, Nina;Kampman, Ellen;Weijenberg, Matty P;Gsur, Andrea;Ulrich, Cornelia M. And the article was included in The American journal of clinical nutrition in 2022.COA of Formula: C8H10NO6P The following contents are mentioned in the article:
BACKGROUND: Folate-mediated 1-carbon metabolism requires several nutrients, including vitamin B6. Circulating biomarker concentrations indicating high vitamin B6 status are associated with a reduced risk of colorectal cancer (CRC). However, little is known about the effect of B6 status in relation to clinical outcomes in CRC patients. OBJECTIVES: We investigated survival outcomes in relation to vitamin B6 status in prospectively followed CRC patients. METHODS: A total of 2031 patients with stage I-III CRC participated in 6 prospective patient cohorts in the international FOCUS (folate-dependent 1-carbon metabolism in colorectal cancer recurrence and survival) Consortium. Preoperative blood samples were used to measure vitamin B6 status by the direct marker pyridoxal 5′-phosphate (PLP), as well as the functional marker HK-ratio (HKr)[3′-hydroxykynurenine: (kynurenic acid + xanthurenic acid + 3′-hydroxy anthranilic acid + anthranilic acid)]. Using Cox proportional hazards regression, we examined associations of vitamin B6 status with overall survival (OS), disease-free survival (DFS), and risk of recurrence, adjusted for patient age, sex, circulating creatinine concentrations, tumor site, stage, and cohort. RESULTS: After a median follow-up of 3.2 y for OS, higher preoperative vitamin B6 status as assessed by PLP and the functional marker HKr was associated with 16-32% higher all-cause and disease-free survival, although there was no significant association with disease recurrence (doubling in PLP concentration: HROS, 0.68; 95% CI: 0.59, 0.79; HRDFS, 0.84; 95% CI: 0.75, 0.94; HRRecurrence, 0.96; 95% CI: 0.84, 1.09; HKr: HROS, 2.04; 95% CI: 1.67, 2.49; HRDFS, 1.56; 95% CI: 1.31, 1.85; HRRecurrence, 1.21; 95% CI: 0.96,1. 52). The association of PLP with improved OS was consistent across colorectal tumor site (right-sided colon: HROS, 0.75; 95% CI: 0.59, 0.96; left-sided colon: HROS, 0.71; 95% CI: 0.55, 0.92; rectosigmoid junction and rectum: HROS, 0.61; 95% CI: 0.47, 0.78). CONCLUSION: Higher preoperative vitamin B6 status is associated with improved OS among stage I-III CRC patients. This study involved multiple reactions and reactants, such as (4-Formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate (cas: 54-47-7COA of Formula: C8H10NO6P).
(4-Formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate (cas: 54-47-7) belongs to pyridine derivatives. Pyridine has a dipole moment and a weaker resonant stabilization than benzene (resonance energy 117 kJ·mol−1 in pyridine vs. 150 kJ·mol−1 in benzene). Reduced pyridines, namely tetrahydropyridines, dihydropyridines and piperidines, are found in numerous natural and synthetic compounds. The synthesis and reactivity of these compounds have often been driven by the fact many of these compounds have interesting and unique pharmacological properties. COA of Formula: C8H10NO6P